SOURCE: Lipid Sciences, Inc.

May 14, 2008 08:30 ET

Lipid Sciences' Atherosclerosis Regression Data Presented at EuroPCR 2008 Congress

Featured in Late-Breaking Trials Session

PLEASANTON, CA--(Marketwire - May 14, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) -- Dr. Ron Waksman, Associate Director, Division of Cardiology, Washington Hospital Center, Washington, D.C., presented preliminary results and new clinical safety data supporting Lipid Sciences' HDL Selective Delipidation technology during a Late-Breaking Trials session at the EuroPCR 2008 Congress in Barcelona, Spain, yesterday. Dr. Waksman, an internationally-recognized interventional cardiologist, was the principal investigator for the Company's clinical trial, "A Randomized Single-Blind Placebo-Controlled Study to Evaluate the Safety of Lipid Sciences' PDS-2 in Subjects with Acute Coronary Syndrome (ACS)."

The atherosclerosis regression data from this 'first in man' clinical trial, which was conducted at the Washington Hospital Center, showed a trend of regression of coronary atherosclerosis as measured by intravascular ultrasound (IVUS) in the group of 28 patients (14 treatment patients and 14 placebo patients) treated by the Company's proprietary HDL Selective Delipidation technology. The IVUS analysis was conducted at the Cardiovascular Research Institute, MedStar Research Institute, under the direction of Dr. Neil J. Weissman, Director of the Cardiac Ultrasound and Ultrasound Core Laboratories, and a recognized expert in the field.

The IVUS measurements showed that the average total atheroma volume in the target coronary arteries decreased by 12.18 mm3 in the treatment group versus a 2.80 mm3 increase in the placebo group. The effect on the average of the 10 mm most-diseased arterial segments was a 6.24 mm3 decrease for the treated group as compared to a 1.73 mm3 decrease in the placebo group. These trends of regression of coronary atherosclerosis in the treatment group were seen over a treatment time course of only seven weeks and, although they did not reach statistical significance, perhaps due to the small number of patients enrolled in the trial, suggested the potential of this therapy to reverse coronary disease in patients with ACS. The new safety data that were released during this presentation provide further evidence of the clinical safety and feasibility of this therapy.

Dr. Waksman commented, "In patients with ACS, serial autologous infusions of HDL delipidated plasma were shown to be well tolerated by patients, and the process was shown to be clinically feasible and safe. The results are sufficiently encouraging to merit further evaluation of whether this therapy may offer a novel adjunct treatment for patients presenting with ACS, and may ultimately stabilize and regress atherosclerotic plaque."

About EuroPCR 2008

EuroPCR is the official congress of the EAPCI (European Association for Percutaneous Cardiovascular Interventions). EuroPCR contributes to the advancement of education and information on existing and new technologies in the fields of cardiovascular intervention. The purpose of the organization is to provide a platform of expression with the aim of reducing the burden of cardiovascular disease. Participants at this Annual Congress include members of the international interventional community of cardiologists, surgeons, radiologists, angiologists, and allied healthcare partners -- all working together toward improved patient outcome.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Mimetic Peptides and HDL Selective Delipidation) aims to develop treatments to reverse atherosclerosis, a systemic disease caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, SARS, and influenza. In addition, Lipid Sciences believes that this Viral Immunotherapy platform also has applicability to a wide range of viruses impacting animal health -- a diverse market with diseases affecting both food and companion animals.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: our inability to obtain adequate funds; our technologies not proving to be safe or effective; our inability to obtain regulatory approval of our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; our reliance on key suppliers to provide the material necessary to conduct successful pre-clinical and clinical studies; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. To receive the Company's press releases via email, please contact: info@lipidsciences.com.

Contact Information

  • FOR FURTHER INFORMATION CONTACT:
    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    925-249-4031
    Email Contact